Table of Contents
-
Company profile Eli Lilly – Largest pharmaceutical company in the world
- Revenue mix Eli Lilly stock
- Company profile Novo Nordisk – Number 1 in the diabetes business
- Revenue mix of Novo Nordisk stocks
- Eli Lilly forecast for 2025
- The latest Novo Nordisk quarterly figures
- Novo Nordisk forecast for 2025
- Eli Lilly stock: key figures
- Novo Nordisk stock: Key figures
- Valuation of Eli Lilly and Novo Nordisk stocks
- Should you buy Eli Lilly or Novo Nordisk stocks in 2025?
Diabetes and obesity are two diseases that are becoming increasingly important. The WHO (World Health Organization) estimates that around 890 million people were obese in 2022. This trend is expected to continue. By 2030, more than 1 billion people are expected to be affected.
The current number of people with blood sugar disorders is over 800 million (according to the WHO for 2024). This figure has quadrupled since 1990. An increase in diabetes cases is also expected. The reason for these high numbers is the excessive consumption of foods that are processed with a lot of sugar, such as fast food, sugary drinks, sweets, and much more.
In contrast, there are two companies that are successfully combating both diseases with their medications and are already helping many people with their products Zepbound, Wegovy, Ozempic, and Mounjaro, among others.
They are two of the largest pharmaceutical companies in the world, Eli Lilly (ISIN: US5324571083) and Novo Nordisk (ISIN: DK0062498333).
Source: StocksGuide stock price
Both companies have significantly outperformed the market in recent years and brought their investors much joy. However, the situation has taken a turn for the worse in recent months. While Eli Lilly's stock price remains close to its all-time high, Novo Nordisk's stock price has lost around half of its value. The slump is mainly due to the results of studies on the new obesity drug Cagrisema, which delivered an average weight loss of 'only' 22.8 percent instead of the expected 25 percent.
At the same time, the general news situation with possible tariffs on pharmaceutical products in the US also contributed to the negative stock price performance of the Danish pharmaceutical giant.
Source: StocksGuide stock price
Many investors are uncertain. Has Novo Nordisk's growth engine stalled, while Eli Lilly stocks continue to march from one all-time high to the next?
We explore this question and compare the two companies in an Eli Lilly versus Novo Nordisk stock analysis.
Company profile Eli Lilly – Largest pharmaceutical company in the world
Eli Lilly was founded in 1876 by Colonel Eli Lilly in Indiana, USA. Since its early days, the American pharmaceutical company has been researching, developing, manufacturing, and distributing drugs for human medicine. The company launched an insulin preparation on the market as early as 1923. At that time, diabetes was still an incurable disease. This therapeutic area has remained a core business of Eli Lilly to this day.Immunotherapy has also been part of the product portfolio for many decades. As early as 1955, the company succeeded in making the vaccine developed by Jonas Salk against polio suitable for mass use.
Later, the areas of diabetes, oncology, immunotherapy and, in recent years, obesity were added.
The Americans are currently the world's largest pharmaceutical company with a market capitalization of over $800 billion.
Source: Big pharma stocks
The company focuses on diabetes, obesity, oncology, immunotherapy, and neurology.
Zepbound & Mounjaro – Eli Lilly's blockbusters
Given how important Zepbound and Mounjaro are to Eli Lilly's business, let's take a closer look at these two blockbuster drugs.
The success of Lilly's weight loss drugs is based on the same active ingredient, known as tirzepatide. While Mounjaro was launched primarily to combat type 2 diabetes, Zepbound is used exclusively to treat obesity (BMI of 30 or above). Both drugs are injected into the abdomen once a week. The active ingredient tirzepatide binds to two proteins in the pancreas, GLP-1 and GIP. These are also known as incretins. The increased release of these proteins makes the patient feel fuller for longer after a meal. It also suppresses the feeling of hunger. This can help prevent cravings in particular. In a 72-week study, patients taking Zepbound lost an average of over 20 percent of their body weight (at the highest dosage of 15 mg).
This means that Eli Lilly currently has the drug with the highest weight loss on the market.
In addition, further positive effects of Zepbound are known or are in the approval phase. For example, Zepbound can now also be used in the US to treat obstructive sleep apnea. It is also expected to significantly reduce the risk of cardiovascular disease (e.g., heart attack). However, Zepbound has not yet been approved for this indication by the US Food and Drug Administration (FDA).
Both drugs are very well positioned on the global market for obesity. In addition, Zepbound is currently only available in the US and could see high sales growth in the long term following approval in other countries.
Revenue mix Eli Lilly stock
In 2024, Eli Lilly generated revenue of $45 billion. Compared to the $34 billion from the previous year, this represents an impressive increase of 32 percent. This is a very high growth rate for an established pharmaceutical company.
Source: Eli Lilly Presentation
The majority of sales were generated in the US. Over $30 billion, around two-thirds, was achieved in the home country.
Sales in the US rose by 39 percent. Of this, 31 percent is attributable to increased sales volumes. Eight percent was achieved through higher prices per drug sold.
The second most important market for the Americans is the EU. With 6.9 billion, Europe accounts for 15 percent of sales. However, sales growth of 12 percent is significantly slower than in the US. There is a good reason for this, as we will see in a moment.
In China and Japan, the combined share of sales is less than 8 percent. All other countries are grouped together as “Rest of the World” and account for 9 percent with around $4.3 billion.
We will now go through the individual segments of Eli Lilly.
Diabetes & Obesity
The Cardiometabolic Health division is the most important division of Eli Lilly. It combines the diabetes and obesity businesses.
This division accounts for around 65 percent of sales.
Source: Eli Lilly 10-K 2024
Of the approximately $45 billion in annual sales, around 50 percent (approximately $22 billion) was generated by the sale of diabetes and obesity drugs in the US.
Of this, the two “miracle drugs” Zepbound and Mounjaro account for approximately 63 percent of US sales or over 50 percent of global sales in this division.
It should be noted once again that Zepbound is currently only approved in the US, meaning that its share of sales could increase even further once it is also approved in the EU. With Humalog, the company has another insulin drug with high sales growth.
Eli Lilly can afford declines in the diabetes segment with the drugs Trulicity and Jardiance. These insulin drugs are becoming partially obsolete through their use with Mounjaro, meaning that part of the diabetes business is being cannibalized by the tirzepatide preparations. In the foreseeable future, Eli Lilly wants to launch a GLP-1 drug to compete with Novo Nordisk's Ozempic. Results from a successful Phase 3 study on Orforglipron (a once-daily pill) were recently reported. If this drug is approved worldwide, it would further increase sales in this division.
Otherwise, we note that the high sales growth in this division is primarily attributable to the high volume growth of incretin drugs.
Oncology
Eli Lilly not only offers highly successful drugs for diabetes and obesity, but also a broad portfolio of products for various types of cancer.
Source: Eli Lilly 10-K 2024
Lilly's oncology division contributed around 20 percent of total sales with $8.7 billion. This division also posted strong sales growth of over 30 percent. This increase is largely attributable to the blockbuster drug Verzenio, a breast cancer treatment administered in tablet form. This drug accounts for 60 percent of the oncology division's sales.
Immunology, neuroscience, and others
Somewhat less prominent are the fields of immunology, neurology, and others.
Source: Eli Lilly 10-K 2024
However, the immunology sector also boasts another high-growth blockbuster drug in the form of Taltz. This is a treatment for plaque psoriasis, a skin condition. Together, these three divisions account for 15 percent of total sales.
Looking at the sales mix, it is clear that future earnings will depend particularly on the success of diabetes and obesity drugs. To this end, Eli Lilly must meet high demand while continuing to invest heavily in research and development of new products.
Source: Eli Lilly & Novo Nordisk R&D / Revenue
Eli Lilly has spent an average of a quarter of its revenue on research and development in recent years. These costs have paid off very well recently and have continued to close the gap between the Americans and Novo Nordisk.
Company profile Novo Nordisk – Number 1 in the diabetes business
Novo Nordisk is known worldwide as the market leader for diabetes products. For decades, the company based in Bagsvaerd near Copenhagen has offered a broad portfolio of diabetes medications.
However, since the launch of the two blockbusters Wegovy and Ozempic, the focus has shifted significantly toward obesity.
Ozempic is perceived by the public as an obesity drug, although it was launched as a GLP-1 product and is intended to help diabetics release insulin and thus support blood sugar regulation.
Wegovy, on the other hand, is approved as an obesity drug and, like Zepbound and Mounjaro, is administered as a weekly injection.
While the Danish pharmaceutical company's stock price performed very well for many years, investors had to cope with a drawdown of over 50 percent within a year.
Source: StocksGuide underwater chart
While Eli Lilly stocks are trading less than 8 percent below their all-time high, Novo Nordisk investors need to keep their nerves steady after the price slump. What led to the sell-off in the stock?
The financial world is increasingly concerned that Novo Nordisk's pipeline will not produce any new blockbusters and that the company could very soon hit a plateau after the high growth rates of recent years.
The Danish management is trying to prevent this with high spending on acquisitions and investments.
Source: annual report Novo Nordisk 2024
In the past fiscal year, 45 percent of revenue was invested in investments and acquisitions. Three years earlier, this figure was only 4 percent.
With the acquisition of US manufacturing company Catalent, Novo Nordisk secured production capacity in the US, enabling it not only to better meet the high demand for Wegovy and Ozempic, but also to avoid a potential scenario of import tariffs on pharmaceutical products into the US. This deal could therefore pay off quickly for the company.
To expand its reach, Novo Nordisk recently entered into a strategic partnership with Hims & Hers. Hims subscribers can access Novo Nordisk's direct-to-consumer platform NovoCare Pharmacy via the Hims portal, securing capacity for Wegovy. This partnership could quickly pay off for both sides.
The budget for research and development has also been increased recently.
Source: Eli Lilly & Novo Nordisk R&D / Revenue
After spending only around 12 percent of their revenue on research into new drugs during the coronavirus pandemic, the Danes have recently increased their resources. Nevertheless, it is clear that Eli Lilly is allocating significantly more of its budget to the development of new drugs. While R&D spending at Novo Nordisk currently stands at 16 percent, the Americans are allocating an average of a quarter of their revenue to research into new active ingredients. It will only become clear in the coming years whether the high spending on research and development will pay off.
Novo Nordisk competition and pipeline
Investors suffered a 27 percent loss in one day when Novo Nordisk presented the initial study results for its weight loss drug Cagrisema in December 2024. Instead of the 25 percent weight loss after 68 weeks targeted by the company, the test subjects were only able to lose an average of 22.7 percent of their body weight. Why are investors so disappointed? On the one hand, Novo Nordisk's management itself set the 25 percent target and failed to achieve it in the first two studies. On the other hand, Eli Lilly already has a product on the market, Zepbound, that promises similar success. However, 40 percent of participants achieved weight loss of 25 percent or more, and only 57 percent of participants chose the maximum dose. In further studies, the average weight loss could therefore be increased with a higher dosage. However, Cagrisema is more complex to manufacture as it is a so-called 2-chamber injection. Further clinical studies will show whether Cagrisema can become a new blockbuster drug.
Another reason for the weak performance of Novo Nordisk stocks is the news from its competitors. More and more pharmaceutical companies are entering the high-growth obesity market, which is expected to be worth $130 billion by 2030.
For example, the American pharmaceutical giant Pfizer is working on an obesity drug in tablet form. These efforts have since been discontinued due to severe side effects. In addition, Amgen, another US company, has started two Phase 3 trials with its drug MariTide. This drug only needs to be injected once a month and showed weight loss of around 17 percent in Phase 2 trials. However, the dose is planned to be increased in the ongoing trial to achieve weight loss of over 20 percent.
Swiss pharmaceutical giant Roche also wants to establish itself in the market for obesity and has announced a deal with Danish company Zealand Pharma. For $5.3 billion, Roche will be able to market the drug Petrelintide together with Zealand Pharma. Initial studies have already shown a respectable 8.6 percent weight loss after 16 weeks of use. The study also showed that the drug was very well tolerated. The American pharmaceutical giant AbbVie has also sought support in Denmark and reached an agreement with the company Gubra A/S for the development and distribution of an amylin product.
However, it should be emphasized that none of the drugs mentioned have been approved yet and further results are needed to show whether the side effects are low enough to allow approval.
In addition, Novo Nordisk also has a full pipeline of other drugs for obesity that are in various stages of testing.
Source: Novo Nordisk Investor Presentation
An oral weight loss drug is set to be approved shortly. With Cagrisema, we already have a potential drug for the future. Promising test results in phase 1 trials showed that the oral preparation Amycretin is very well tolerated and enabled test subjects to achieve weight loss of up to 22 percent in a 36-week study.
Nevertheless, it can be said that despite increasing competitive pressure, Novo Nordisk's market position does not appear as bad as market participants currently assess it. Many price movements of companies in this sector appear to be driven by news about study results.
Revenue mix of Novo Nordisk stocks
Let's take a quick look at the composition of revenue at Novo Nordisk.
Unsurprisingly, Wegovy and Ozempic dominate.
Source: annual report Novo Nordisk 2024
The GLP-1 drug Ozempic alone accounted for 41 percent of sales in 2024, while Wegovy generated a 20 percent stock.
The Danish pharmaceutical group's total sales growth was 25 percent. Sales of Ozempic also increased by 25 percent. Wegovy posted an impressive growth rate of 85 percent.
The growth rates for the two blockbusters are impressive, but the overview reveals further positive trends. The insulin division recorded 15 percent sales growth and has two promising products in its portfolio: Tresiba and NovoRapid. With Awigli, Novo Nordisk has only been offering a once-weekly insulin injection for type 1 diabetes patients since fall 2024. It is currently only available in China, Canada, and Germany. Approval by the US FDA is still pending, but Awigli is the only weekly insulin replacement currently available on the market. If the FDA approves it, sales of this drug could accelerate.
Although we see that Novo Nordisk is heavily dependent on the growth of its two top products, Wegovy and Ozempic, the Danish company's current product portfolio certainly has more to offer. The insulin preparations segment also has the potential to deliver good growth figures.
A few weeks ago, Eli Lilly and Company reported its quarterly figures. Growth in all areas is outstanding. While sales rose by 45 percent to USD 13.5 billion and the gross margin increased by almost the same amount, net income (TTM) doubled compared with the same quarter of the previous year.
Source: financial data Eli Lilly
EBIT rose by 85 percent to approximately $5.7 billion. By contrast, cost increases in sales and administration as well as research and development were moderate.
As these results were reported before Donald Trump's tariffs were imposed, the management's outlook in the following earnings reports will be all the more important for investors. Nevertheless, the results are very good and demonstrate Eli Lilly's dominant position in the pharmaceutical sector.
Eli Lilly forecast for 2025
Will the impressive growth of Eli Lilly continue? Analysts do not see any signs of a slowdown. In fact, growth is expected to accelerate even further in all areas this year.
Source: sales and margin forecast
The expected revenue in 2029 of over US$100 billion would be more than double the current year's figure. The forecast for this year is around $60 billion. This would represent an increase of 32 percent compared to the previous year. If the sales forecasts for 2029 are met, annual sales growth would be 14.4 percent, which would be very high for a pharmaceutical company of this size.
This is currently supported by Eli Lilly's market position, as no competitor other than Novo Nordisk has similarly effective drugs in the diabetes and obesity sector, and the global rollout of the products has not yet been completed. If another player were to establish itself with a better tolerated and equally successful weight loss product, the forecasts would have to be adjusted downward.
Even higher growth rates are expected for net income.
Source: Eli Lilly forecast
The average profit margin for 2029 is expected to be 45 percent. This would represent an increase of almost 100 percent compared to the net margin in 2024. In addition, revenue is expected to reach $46.3 billion in 2029. Based on the net income for 2024, this would represent an annual growth rate of 26.9 percent.
These estimates appear very high and unrealistic at first glance. However, if Eli Lilly's products continue to maintain their market leadership, the growth rates could well be accurate. Nevertheless, a certain degree of caution may be warranted, as the pharmaceutical industry as a whole is shifting strongly toward the obesity market and other players could establish their products on the market by 2029.
The latest Novo Nordisk quarterly figures
The latest quarterly figures reported by Novo Nordisk are hardly inferior to those of Eli Lilly.
Revenue increased by 30 percent to DKK 85.7 billion (Danish kroner). This corresponds to around USD 13.1 billion.
Source: financial data Novo Nordisk
EBIT rose by 44 percent to DKK 38.5 billion (USD 5.84 billion) and net profit increased by 29 percent to DKK 28.2 billion (USD 4.28 billion). There was a significant increase in research and development costs, while sales and administrative costs were reduced.
These growth figures are lower than those reported by Eli Lilly. Nevertheless, they are still impressively high growth rates for an established pharmaceutical company.
Novo Nordisk forecast for 2025
How do analysts view the future growth of Novo Nordisk?
There are no signs of a slowdown in revenue growth yet.
Source: Novo Nordisk forecast
Sales are expected to increase to DKK 542 billion by 2029, corresponding to an annual growth rate of 11 percent. The estimate for the current year 2025 is 20 percent.
There is still some skepticism surrounding Novo Nordisk, as these estimates do not yet include tariffs on pharmaceutical products in the US. Should Donald Trump introduce these, it could prove to be a setback for the Danish pharmaceutical giant.
The net margin is expected to develop to 40 percent by 2029 and currently stands at around 35 percent.
Source: Novo Nordisk forecast
Net profit could rise to DKK 220 billion ($33.4 billion) by 2029, more than doubling in six years if the estimates prove accurate.
In this case, Eli Lilly would overtake Novo Nordisk in terms of annual net income, as the Danish company currently still leads Eli Lilly by DKK 101 billion ($15.3 billion) ($11.1 billion).
Novo Nordisk is currently investing heavily in expanding its pipeline so as not to be left behind by Eli Lilly. By 2029, competitors such as Roche, Amgen or another pharmaceutical company could have developed and approved their own obesity products.
These forecasts should therefore be treated with a degree of caution.
Eli Lilly stock: key figures
Unlike many other pharmaceutical stocks, the Eli Lilly stock cannot be classified as a dividend stock. With a current score of 10 points, it is two points short of being listed as a top performer according to the dividend strategy. Nevertheless, it may be interesting to take a look at the profit distributions.
Source: Eli Lilly dividend
For over 10 years, long-term investors have received annually increasing dividends. However, the current dividend yield is only 0.6 percent.
Source: Eli Lilly dividend
The annual increases of 15 percent over the last five years are impressive. For investors who bought in ten years ago at prices around $85, this results in a yield on investment of over 7 percent based on the probable annual dividend of $6 in 2025. This illustrates the effect of continuous dividend increases over a longer period of time. The Americans have the payout ratio under control. The average ratio was 55 percent based on data from the last three years.
In recent years, management has bought back stocks, albeit to a much lesser extent. The number of outstanding stocks has been reduced by only 2 percent. This is due to high investments in the existing business and the significant dividend increase.
Long-term investors have not only enjoyed a tenfold increase in the stock price over the past 10 years, but also rising dividend payments.
Novo Nordisk stock: Key figures
Let's take a look at the Novo Nordisk stock for comparison. Investors in the Danish pharmaceutical giant have also been rewarded for their long-standing loyalty with steady dividend increases. The company has increased its profit distribution every year for over 20 years.
Source: Novo Nordisk dividend
The Danes have 11 points and are therefore not among the top scorers according to the dividend strategy. However, the current dividend yield is significantly higher than that of Eli Lilly and, at around 2.83 percent, is higher than it has been for a long time.
Source: Novo Nordisk dividend
The average payout ratio of 50 percent over the last three years gives the company sufficient scope for investment or debt repayment. At 22 percent per annum over the last five years, dividend growth is even better than Eli Lilly's 15 percent.
Stocks have also been bought back by the Danish management, reducing the number of outstanding stocks by around 7 percent.
Novo Nordisk's management has also focused on shareholder value with high dividend increases and stock buybacks. The dividend yield is currently higher than in previous years and appears more attractive than at Eli Lilly.
Valuation of Eli Lilly and Novo Nordisk stocks
Here is a comparison of the two companies. Both companies have recently achieved fantastic revenue growth and, based on the analysis so far, analysts do not foresee any significant slowdown.
What are the key valuation figures for Eli Lilly and Novo Nordisk?
Source: key performance indicators
The key figures could hardly be more contrasting. Novo Nordisk's price-earnings ratio (P/E ration) currently stands at 18, while the American company's figure is 77. Novo Nordisk's average P/E ratio over the last six years was 32, almost twice as high. Lilly's average is 57, which is within the range of the current valuation. This makes the Danish pharmaceutical company's stocks appear attractive.
With an enterprise value/sales (EV/sales) ratio of 6.4, Novo Nordisk is well below Eli Lilly's sales multiple of 19. In the current environment, investors usually only pay such a high multiple for companies that require very little capital and can generate high network effects. However, this is not the case with Eli Lilly.
A look at the price-to-earnings growth ratio (PEG) could provide some more insight. A value below 1 could indicate a favorable valuation, even if the P/E ratio appears high. Eli Lilly's EBIT grew by 65 percent last year, resulting in a PEG ratio of 1.18.
Source: Eli Lilly PEG
At first glance, this does not seem high for a rapidly growing market leader. However, it should be noted that this figure is only 0.65 for Novo Nordisk (P/E ratio of 18 and EBIT growth of 27 percent).
After looking at three relevant valuation metrics, Novo Nordisk stocks currently appear very cheap, especially given the growth opportunities and average valuation in the past. Eli Lilly stocks, on the other hand, appear very highly valued. The current stock price seems to price in high growth expectations, which could increase the risk of a price slide if these expectations are not met.
Source: Novo Nordisk vs. Eli Lilly
To complete the comparison, let's look at some other key figures. Eli Lilly's revenue per employee is $960,000, well above Novo Nordisk's $3.81 million (DKK 580,000). The Americans therefore appear to be using their staff much more efficiently.
The return on equity is very high for both companies, at 70 percent and 74 percent respectively, indicating a very good return on capital.
Eli Lilly's revenue growth is currently above that of Novo Nordisk, and this trend could continue as Eli Lilly appears to have another ace up its sleeve with the global distribution of Zepbound. The high growth of Verzenioscould also help Eli Lilly to outpace Novo Nordisk in terms of sales growth. For this reason, it is not surprising that Eli Lilly also came out ahead in terms of EBIT growth recently. However, Novo Nordisk's free cash flow margin of 25 percent is well above Eli Lilly's figure of 8 percent. The reasons for this can be found in the cash flow statements of both companies.
Source: financial data Eli Lilly
In 2024, the Americans managed to convert around 83 percent of their net profit into operating cash flow. That is 20 percent of sales. Both figures are good, but Novo Nordisk is clearly ahead here.
Source: financial data Novo Nordisk
The Danes, on the other hand, converted 120 percent of their net profit into operating cash flow. The cash flow margin is 42 percent. Many SaaS companies do not achieve this margin, which demonstrates the outstanding cash generation that Novo Nordisk achieves with its products.
However, Eli Lilly is achieving significantly higher growth, while Novo Nordisk is particularly dependent on its two drugs, Wegovy and Ozempic.
Should you buy Eli Lilly or Novo Nordisk stocks in 2025?
After a detailed analysis of both companies, we have now reached our conclusion. At Eli Lilly & Company, everything seems to be going according to plan at the moment. The pipeline is delivering more and more blockbusters, and the current drugs could generate high growth for years to come. This seems to be rewarded by investors with high expectations and a correspondingly high valuation premium. The Americans must also fulfill these expectations, otherwise there could be a threat of a price slump.
We have already seen this price slump in the stock price of Novo Nordisk over the last six months, when high expectations were not met. Disappointing study results, emerging competition, and a volatile market environment have led to a drawdown of almost 60 percent, which is unprecedented in the company's history. This may be a favorable entry point for interested investors in a quality company that has been established on the market for many years and enjoys a leading market position. The current valuation is well below the average of previous years, and the dividend has been steadily increasing for many years.
The impression is that Novo Nordisk stocks are currently trading at a significant discount, while no price seems too high for Eli Lilly stocks.
Analysts were recently divided on Novo Nordisk, which led to different recommendations.
Source: Novo Nordisk Upgrades & Downgrades
Of the last seven recommendations, the stock has been rated “sell” once, “hold” three times, and “buy” four times. This trend is also confirmed overall.
Source: Novo Nordisk forecast
27 analysts have issued a rating for the stock. 62 percent of experts consider the security a buy. 30 percent would only hold the stock, and 9 percent would still sell even at the reduced price level. The price targets issued range widely from DKK 350 to DKK 1,150.
By contrast, analysts are unanimous in their assessment of Eli Lilly stocks.
Source: Eli Lilly Upgrades & Downgrades
All ratings in 2025 were buy recommendations. Overall, there is also little caution regarding the American stock.
Source: Eli Lilly forecast
90 percent of all experts would still buy the stock at its current price level. Only three analysts recommend holding the stock. No analyst rates the stock as a sell. However, the upside potential is limited at around 16 percent.
Both companies will be presenting their quarterly figures shortly. With Eli Lilly stocks in particular, it may be advisable to wait for this announcement to see whether the Americans can confirm their high growth in the current market environment. Despite the high growth forecasts for the coming years, it could be worthwhile setting an EV/sales alert of, for example, 12 in order to re-examine the security.
Investors will also be watching closely when Novo Nordisk reports its quarterly figures to see whether management can confirm its forecast or whether Wegovy and Ozempic are losing market share. At the current price level, the stock appears to be attractively valued compared to its American competitor, and the stock price may have bottomed out after a long downward phase. This could present a good entry opportunity for interested investors.
Cautious investors could set up a P/E alert at a value of 15 to potentially gain an even greater margin of safety.
The author and/or persons or companies associated with the StocksGuide own or may own stocks in Eli Lilly or Novo Nordisk.
This post represents an expression of opinion and not investment advice. Please note the legal information.
